Monitor the company's next 10-Q for confirmation of the offering's completion and actual net proceeds, as well as any updates on the use of proceeds for clinical development programs.
Price Chart
Executive Summary
Nektar Therapeutics raised approximately $325 million through an upsized public offering of 3,532,609 shares at $92.00 per share, with net proceeds estimated at $350.9 million after underwriting discounts and expenses. The company granted underwriters a 30-day option to purchase up to an additional 529,891 shares, which was exercised in full.
Key Financial Metrics
Key Facts
- Nektar Therapeutics conducted an upsized public offering of 3,532,609 shares of common stock at $92.00 per share
- Gross proceeds from the offering are expected to be approximately $325 million
- Net proceeds are estimated at $350.9 million after underwriting discounts and commissions
- The company granted underwriters a 30-day option to purchase up to an additional 529,891 shares, which was exercised in full
- Proceeds will be used for general corporate purposes including research and development, clinical development, and manufacturing costs
Financial Impact
Raised $325 million gross ($350.9 million net) through issuance of 3,532,609 shares at $92.00 per share
Risk Factors
- Dilution to existing shareholders from the issuance of new shares
- Potential misallocation of proceeds if not used effectively for clinical development
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 7 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-171731 |
| Document: d80358d8k.htm | 0001193125-26-171731 |
| Document: d80358dex991.htm | 0001193125-26-171731 |
| Document: d80358dex51.htm | 0001193125-26-171731 |
| Document: 0001193125-26-171731-index-headers.html | 0001193125-26-171731 |
| Document: 0001193125-26-171731-index.html | 0001193125-26-171731 |
| Document: 0001193125-26-171731.txt | 0001193125-26-171731 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 13, 2026 9w ago | Press Release | $73.02 $68.50 | ▼ −6.19% | ▼ −4.20% | $35.78 (−51.00%) |
Aug 9, 2026 10w ago | Institutional Cluster | $74.86 $75.44 | ▲ +0.77% | ▲ +1.69% | $35.78 (−52.20%) |
Aug 7, 2026 10w ago | Court Ruling | $76.48 $74.19 | ▼ −2.99% | ▼ −2.60% | $35.78 (−53.22%) |
Jul 28, 2026 11w ago | Press Release | $70.68 $73.77 | ▲ +4.37% | ▼ −0.65% | $35.78 (−49.38%) |
Jun 11, 2026 18w ago | Institutional Cluster | $59.21 $72.92 | ▲ +23.15% | ▲ +21.26% | $35.78 (−39.57%) |
Jun 11, 2026 18w ago | Institutional Cluster | $59.21 $72.92 | ▲ +23.15% | ▲ +21.26% | $35.78 (−39.57%) |
May 21, 2026 21w ago | Insider Cluster | $66.61 $65.25 | ▲ +2.04% | ▲ +0.63% | $35.78 (+46.28%) |
May 8, 2026 23w ago | 8-K | $78.72 $56.23 | ▲ +28.57% | ▲ +28.27% | $35.78 (+54.55%) |
May 7, 2026 23w ago | 8-K | $81.89 $57.32 | ▼ −30.00% | ▼ −30.03% | $35.78 (−56.31%) |
Apr 24, 2026 25w ago | DEFA14A | $86.74 $65.56 | ▼ −24.42% | ▼ −29.37% | $35.78 (−58.75%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access